Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers

Journal of Psychopharmacology

Volumn 24, Issue 11, 2010, Pages 1689-1696

  Zuurman, Lineke ^a   Passier, Paul C C M ^b   Kam, Marieke L De ^a   Kleijn, Huub J ^b   Cohen, Adam F ^b   Gerven, Joop M A Van ^b  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b NV ORGANON   (Netherlands)

Author keywords

cannabinoid; CB1 receptor agonist; healthy volunteers; human; intravenous; Org 26828; pharmacodynamics; pharmacokinetics; sedation

Indexed keywords

CANNABINOID 1 RECEPTOR AGONIST; DRUG METABOLITE; MIDAZOLAM; ORG 26761; ORG 26828; UNCLASSIFIED DRUG;

ADULT; AMNESIA; ANGINA PECTORIS; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BODY POSTURE; CARDIOVASCULAR EFFECT; CHEMICAL ANALYSIS; CLINICAL TRIAL; CONSCIOUS SEDATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; DYSPNEA; HALLUCINATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NORMAL HUMAN; OUTPATIENT; PARANOIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; URINALYSIS; VOMITING;

ADULT; AMBULATORY SURGICAL PROCEDURES; CONSCIOUS SEDATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDAZOLAM; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL; YOUNG ADULT;

EID: 78650132963     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109106913     Document Type: Article

References (18)

1. Ameri A. (1999) The effects of cannabinoids on the brain. Prog Neurobiol 58: 315-348.
2. Bond A., Lader M. (1974) The use of analogue scales in rating subjective feelings. Brit J Med Psychol 47: 211-218.
3. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP (1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88: 82-88.
4. de Roode A., van Gerven JM, Schoemaker RC, et al. (2000) A comparison of the effects of propofol and midazolam on memory during two levels of sedation by using target-controlled infusion. Anesth Analg 91: 1056-1061.
5. de Visser S., van der Post J., de Waal P., Cornet F., Cohen A., van Gerven J. (2003) Biomarkers for the effect of benzodiazepines in healthy volunteers. Brit J Clin Pharmacol 55: 39-50. (Pubitemid 36110838)
6. D'Souza DC, Perry E., MacDougall L., et al. (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558-1572.
7. Grotenhermen F. (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42: 327-360.
8. Hall W., Solowij N. (1998) Adverse effects of cannabis. Lancet 352: 1611-1616.
9. Lever IJ, Rice AS (2007) Cannabinoids and pain. Handbook of Experimental Pharmacology 177: 265-306.
10. Russo E. (2006) A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66: 234-246.
11. Sidney S. (2002) Cardiovascular consequences of marijuana use. J Clin Pharmacol 42: 64S - 70S.
12. Schmitt JAJ (2001) Serotonin, caffeine and cognition: psychopharmacological studies in human cognitive functioning. Thesis. Maastricht: NeuroPsych Publishers.
13. Tramer MR, Carroll D., Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Brit Med J 323: 16-21.
14. Wright BM (1971) A simple mechanical ataxia-meter. J Physiol 218: 27P - 28P.
15. Zuurman L., Passier Pccm, de Kam ML, Kleijn HJ, Cohen AF, van Gerven JMA (2009) Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers. J Psychopharmacol 23 (6). 633-644.
16. Zuurman L., Roy C., Schoemaker RC, et al. (2008 a) Effect of intrapulmonary THC administration in humans. J Psychopharmacol 22: 707-716.
17. Zuurman L., Roy C., Schoemaker RC, et al. (2008 b) Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625. J Psychopharmacol (accessed 21 November 2008 ).
18. Zuurman L., van Gerven JMA, Asgarali F., Burggraaf J. (2006) Effect of acute THC administration on heart rate variability in humans. Brit J Clin Pharmacol 61: 485-486.